The FDA is planning on imposing severe restrictions on the sale of e-cigarette products as soon as next week; marijuana was a hit with voters in the midterm election; HHS is recommending a ban on the chemicals in kratom that would make the herb as illegal as heroin or LSD.
The FDA is planning on imposing severe restrictions on the sale of e-cigarette products as soon as next week, The Washington Post reported. The ban would come as public health experts are alarmed by a huge increase in vaping among minors. The agency will also impose such rules as age-verification requirements for online sales, and it is expected to propose banning menthol in regular cigarettes.
Marijuana was a hit with voters in the midterm elections, The Hill reported. In Missouri and Utah, voters approved medical cannabis, and in Michigan, voters legalized the adult use, cultivation, and retail marketing of marijuana. In 4 states—Connecticut, Michigan, Minnesota, and Illinois—voters elected governors who openly campaigned on a platform that included legalizing adult marijuana use. In California and Colorado, voters elected governors who have spearheaded legalization reform efforts. In Maine and in New Mexico, 2 antimarijuana governors were replaced by candidates seeking cannabis reforms.
HHS is recommending a ban on the chemicals in kratom that would make the popular herbal supplement as illegal as heroin or LSD by classifying them as Schedule I substances, according to STAT News. Some scientists are worried that a ban would stifle research on chemicals that could be developed into opioid alternatives and said that banning kratom would harm people who are currently using the substance.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More